Granules Life Sciences Pvt Ltd facility receives EIR from USFDA

Granules Life Sciences Private Limited (GLS), a wholly owned subsidiary of Granules India Limited situated in Hyderabad, has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for the first inspection conducted from July 28, 2025 to Aug 01, 2025. This approval confirms the facility's compliance with FDA quality standards and regulatory requirements.

Granules Life Sciences Private Limited is engaged in the manufacturing of PFI & Finished Dosages.

Shares of Granules India Limited was last trading in BSE at Rs. 574.50 as compared to the previous close of Rs. 565.00. The total number of shares traded during the day was 47572 in over 1725 trades.

The stock hit an intraday high of Rs. 577.00 and intraday low of 564.85. The net turnover during the day was Rs. 27245519.00.

Source : Equity Bulls

Keywords

GranulesIndia INE101D01020 Pharmaceuticals GranulesLifeSciences USFDA EIR Hyderabad